Auhtors: Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, et al.
PMID: 36807772 PMCID: PMC10242329 DOI: 10.1002/cam4.5698
Abstract
Cancer is now considered a tumor microenvironment (TME) disease, although it was originally thought to be a cell and gene expression disorder. Over the past 20 years, significant advances have been made in understanding the complexity of the TME and its impact on responses to various anticancer therapies, including immunotherapies. Cancer immunotherapy can recognize and kill cancer cells by regulating the body’s immune system. It has achieved good therapeutic effects in various solid tumors and hematological malignancies. Recently, blocking of programmed death-1 (PD-1), programmed death-1 ligand-1 (PD-L1), and programmed death Ligand-2 (PD-L2), the construction of antigen chimeric T cells (CAR-T) and tumor vaccines have become popular immunotherapies Tumorigenesis, progression, and metastasis are closely related to TME. Therefore, we review the characteristics of various cells and molecules in the TME, the interaction between PD-1 and TME, and promising cancer immunotherapy therapeutics.
Keywords: PD-1; PD-L1; cancer immunotherapy; cancer progression; tumor microenvironment.
Source: https://pubmed.ncbi.nlm.nih.gov/36807772/
Archive: https://archive.is/9xcso
